• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » IM Olanzapine Plus Benzodiazepines: Safe or Unsafe?

IM Olanzapine Plus Benzodiazepines: Safe or Unsafe?

September 13, 2021
Victoria Hendrick, MD. and Daniel Carlat, MD
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Victoria Hendrick, MD. Editor in Chief, The Carlat Hospital Psychiatry Report. Chief, Inpatient Psychiatry, Olive View UCLA Medical Center.

Daniel Carlat, MD. Publisher, The Carlat Hospital Psychiatry Report.

Dr. Hendrick and Dr. Carlat have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The Eli Lilly warning followed reports of 160 adverse events, including 29 fatalities, linked to IM olanzapine/IM benzodiazepine combinations from January 2004 to September 2005 (Marder SR et al, J Clin Psychiatry 2010;71(4):433–441). Looking closely at these cases, it is unclear that this medication combination actually caused the fatalities. Many of them occurred days after the olanzapine injection (n = 12) or involved patients with serious medical illnesses or suicide attempts (n = 14), either of which may have been the actual cause of death.

In addition, subsequent controlled trials appear to show that IV and IM olanzapine are safe when combined with benzodiazepines. A double-blind, randomized controlled study that compared IV olanzapine 5 mg combined with IV midazolam 2.5–5 mg (n = 109) to IV midazolam alone (n = 115) found that the olanzapine/midazolam combination produced more rapid sedation than midazolam alone and was safe and well tolerated (Chan EW et al, Ann Emerg Med 2013;61(1):72–81). Another study of hospital patients (n = 91) who received IM olanzapine (5–10 mg) plus IM lorazepam (1–2 mg) reported no serious adverse events, even among patients who received both medications within a five-minute interval (Williams AM, Ment Health Clin 2018;8(5):208–213). Lastly, in a study that looked at 96 patients who received IM haloperidol (n = 71) or IM olanzapine (n = 25) along with a benzodiazepine, 5% of the patients in the haloperidol plus benzodiazepine group experienced hypotension, while none of the patients in the olanzapine plus benzodiazepine group had this side effect. Also, none experienced decreased oxygen saturation, except for patients who had positive alcohol breathalyzer tests or were visibly intoxicated. The authors concluded that olanzapine plus benzodiazepine is no riskier than haloperidol plus benzodiazepine, provided patients have not ingested significant amounts of alcohol (Wilson MP et al, J Emerg Med 2012;43(5):790–797).

Should we separate the administration of these meds by some time interval? The FDA does not give a clear directive on this point, unlike the European Medicines Agency, which recommends separating olanzapine and benzodiazepines by at least one hour.

The olanzapine + benzodiazepines combination is probably safe for most agitated patients who are otherwise healthy—though it is not our first choice, given the clinical controversies. This combination is best avoided in patients with compromised respiratory function (eg, COPD) or who are intoxicated with alcohol.
Hospital Psychiatry
KEYWORDS antipsychotics benzodiazepines olanzapine psychotic-agitation side-effects
Victoria hendrick 150x150
Victoria Hendrick, MD.

Medications to Rapidly Treat Psychotic Agitation

More from this author
Carlat 150x150
Daniel Carlat, MD

Treating Alcohol Use Disorder—A Fact Book (2023)

More from this author
www.thecarlatreport.com
Issue Date: September 13, 2021
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Agitation, CHPR, October-November-December 2021
Note From the Editor-in-Chief
IM Olanzapine Plus Benzodiazepines: Safe or Unsafe?
Can We Treat Depression by Targeting Inflammation?
Faster Refeeding of Patients With Anorexia Nervosa Appears Safe
Melatonin vs Memantine for ECT-Related Cognitive Impairment
Rapid-Onset Treatment for Pedophilic Disorder
Medications to Rapidly Treat Psychotic Agitation
Anticholinergic Drugs and Risk of Cognitive Impairment and Dementia
Treating Agitation in Patients with Dementia
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    Treating Alcohol Use Disorder: A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto104192710.jpg
    Hospital Psychiatry

    Management of Depression and Neurocognitive Impairment in Patients With HIV

    Strategies for the evaluation and management of HIV-associated mood and cognitive changes and potential drug interactions between psychiatric and antiretroviral medications. 

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.